Literature DB >> 16076956

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Elizabeth J Slow1, Rona K Graham, Alexander P Osmand, Rebecca S Devon, Ge Lu, Yu Deng, Jacqui Pearson, Kuljeet Vaid, Nagat Bissada, Ronald Wetzel, Blair R Leavitt, Michael R Hayden.   

Abstract

We have serendipitously established a mouse that expresses an N-terminal human huntingtin (htt) fragment with an expanded polyglutamine repeat (approximately 120) under the control of the endogenous human promoter (shortstop). Frequent and widespread htt inclusions occur early in shortstop mice. Despite these inclusions, shortstop mice display no clinical evidence of neuronal dysfunction and no neuronal degeneration as determined by brain weight, striatal volume, and striatal neuronal count. These results indicate that htt inclusions are not pathogenic in vivo. In contrast, the full-length yeast artificial chromosome (YAC) 128 model with the identical polyglutamine length and same level of transgenic protein expression as the shortstop demonstrates significant neuronal dysfunction and loss. In contrast to the YAC128 mouse, which demonstrates enhanced susceptibility to excitotoxic death, the shortstop mouse is protected from excitotoxicity, providing in vivo evidence suggesting that neurodegeneration in Huntington disease is mediated by excitotoxic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076956      PMCID: PMC1183566          DOI: 10.1073/pnas.0503634102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

Authors:  R J Carter; L A Lione; T Humby; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

3.  Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.

Authors:  Jeremy M Van Raamsdonk; Jacqueline Pearson; Elizabeth J Slow; Sazzad M Hossain; Blair R Leavitt; Michael R Hayden
Journal:  J Neurosci       Date:  2005-04-20       Impact factor: 6.167

4.  Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

Authors:  C J Cummings; E Reinstein; Y Sun; B Antalffy; Y Jiang; A Ciechanover; H T Orr; A L Beaudet; H Y Zoghbi
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

5.  Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.

Authors:  Aaron B Bowman; Seung-Yun Yoo; Nico P Dantuma; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2005-01-20       Impact factor: 6.150

6.  A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Authors:  J G Hodgson; N Agopyan; C A Gutekunst; B R Leavitt; F LePiane; R Singaraja; D J Smith; N Bissada; K McCutcheon; J Nasir; L Jamot; X J Li; M E Stevens; E Rosemond; J C Roder; A G Phillips; E M Rubin; S M Hersch; M R Hayden
Journal:  Neuron       Date:  1999-05       Impact factor: 17.173

7.  A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

Authors:  Xiaoqian Zhang; Donna L Smith; Anatoli B Meriin; Sabine Engemann; Deborah E Russel; Margo Roark; Shetia L Washington; Michele M Maxwell; J Lawrence Marsh; Leslie Michels Thompson; Erich E Wanker; Anne B Young; David E Housman; Gillian P Bates; Michael Y Sherman; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-10       Impact factor: 11.205

8.  Mutant huntingtin enhances excitotoxic cell death.

Authors:  M M Zeron; N Chen; A Moshaver; A T Lee; C L Wellington; M R Hayden; L A Raymond
Journal:  Mol Cell Neurosci       Date:  2001-01       Impact factor: 4.314

9.  Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

Authors:  I A Klement; P J Skinner; M D Kaytor; H Yi; S M Hersch; H B Clark; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

10.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

View more
  96 in total

Review 1.  Nuclear ataxias.

Authors:  Harry T Orr
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

Review 2.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

4.  Modeling Huntington disease in Drosophila: Insights into axonal transport defects and modifiers of toxicity.

Authors:  Megan Krench; J Troy Littleton
Journal:  Fly (Austin)       Date:  2013-09-10       Impact factor: 2.160

5.  Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.

Authors:  Amy B Ryan; Scott O Zeitlin; Heidi Scrable
Journal:  Neurobiol Dis       Date:  2006-09-15       Impact factor: 5.996

6.  Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.

Authors:  Melissa K Strong; Amber L Southwell; Jennifer M Yonan; Michael R Hayden; Grant R Macgregor; Leslie M Thompson; Oswald Steward
Journal:  J Huntingtons Dis       Date:  2012

Review 7.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

8.  Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease.

Authors:  Junmei Wan; Jeffrey N Savas; Amy F Roth; Shaun S Sanders; Roshni R Singaraja; Michael R Hayden; John R Yates; Nicholas G Davis
Journal:  Chem Biol       Date:  2013-11-07

9.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

10.  Prion-like proteins sequester and suppress the toxicity of huntingtin exon 1.

Authors:  Can Kayatekin; Kent E S Matlack; William R Hesse; Yinghua Guan; Sohini Chakrabortee; Jenny Russ; Erich E Wanker; Jagesh V Shah; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.